Matinas BioPharma Holdings (MTNB) FCF Payout Ratio (2017 - 2018)

Matinas BioPharma Holdings (MTNB) reported FCF Payout Ratio of 0.2 for Q3 2018, down 24454.4% quarter-over-quarter from 0.0 in Q2 2018.

Matinas BioPharma Holdings (MTNB) FCF Payout Ratio (2017 - 2018) Analysis & Trends

Matinas BioPharma Holdings (MTNB) has 2 years of FCF Payout Ratio data on file, last reported at 0.2 in Q3 2018.

FCF Payout Ratio for Q3 2018 came in at 0.2, changed N/A year-over-year; the trailing twelve-month figure through Sep 2018 was 0.1 (changed N/A YoY), and the FY2017 annual result was 0.05, changed N/A from the prior year.
FCF Payout Ratio slipped to 0.2 in Q3 2018 per MTNB's latest filing, from 0.0 in the prior quarter.
Over five years, FCF Payout Ratio peaked at 0.05 in Q4 2017 and troughed at 0.2 in Q1 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Cover (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Matinas BioPharma Holdings	4.60 Mn	2.15 Mn	-	-

Download Data